31-08-2013 t/m 4-09-2013 ESC Congres 2013 Amsterdam (NH)

Auteur Topic: 31-08-2013 t/m 4-09-2013 ESC Congres 2013 Amsterdam (NH)  (gelezen 27492 keer)

0 gebruikers (en 1 gast bekijken dit topic.

oma

  • Senior gebruiker
  • ****
  • Berichten: 10,711
Reactie #100 Gepost op: 3 september 2013, 22:05:38
Impact of statin use on long-term limb outcomes in patients with established PAD: Insights from the REACH Regisry.

REACH Registry


oma

  • Senior gebruiker
  • ****
  • Berichten: 10,711
Reactie #101 Gepost op: 3 september 2013, 22:08:12
Study author Dr. Deepak Bhatt comments on Cangrelor for PCI: the CHAMPION Trial.

CHAMPION Trial


oma

  • Senior gebruiker
  • ****
  • Berichten: 10,711
Reactie #102 Gepost op: 3 september 2013, 22:10:36
Centenary of the Tour de France Group: Mortality of French Participants from the Tour de France 1947-2012.

Tour de France

....fietsen is goed voor je hart en Nederlanders moeten een helm dragen van de Amerikaanse hartdokters


oma

  • Senior gebruiker
  • ****
  • Berichten: 10,711
Reactie #103 Gepost op: 3 september 2013, 22:59:45
Author: Marco Tubaro (Rome, Italy)

The general issue of this symposium was the last “link” of the chain of survival, namely post- resuscitation care.

Prof. Koster from Amsterdam (The Netherland) showed the changes between the older and newer ILCOR guidelines, particularly regarding compression: the ventilation ratio (which switched from 15:2 to 30:2) and the extended use of the automatic external defibrillator (AEDs). The importance of therapeutic hypothermia (TH) and of coronary revascularization with PCI were stressed, since in the ILCOR guidelines TH has a class I indication for patients with return of spontaneous circulation (ROSC) after an out-of-hospital cardiac arrest (OHCA) due to ventricular fibrillation (shockable rhythm) and a class IIa indication in case of other cardiac rhythms.

On top of TH, other supportive measures were alluded to, such as normoglycaemia, haemodynamic optimization, anticonvulsive therapy, as well as oxygen management. Moreover, in a paper by Dumas et al, the rate of occluded infarct-related artery was 87% in case of ST elevation on the ECG, but also 63% in case of chest pain without ST elevation, suggesting an important role for urgent coronary angiography and PCI if needed. However, in spite of the good data in the literature, the implementation of TH and coronary angiography ± PCI for ROSC patients after OHCA is still lagging behind in the cardiological community, because, in order to implement a therapeutic strategy, medical science should work together with educational efficiency and local organization. OHCA systems of care should be implemented, linking the EMS with hospitals with 24/7 PCI and ICU facilities, as well as with TH capability. TH can be given at the same time (with good results, as in Dr. Noc’s experience in Slovenia) or after successful PCI. Quality control and specific reimbursement have also a key role for implementing this OHCA system of care.

Dr. Boettiger from Koln (Germany) talked about TH. He started with the first proposal of TH in a guideline, dating back to 1961. Many dangerous pathophysiological pathways have long been known to cause damage to the brain before, during and after cardio-pulmonary resuscitation (CPR) and ROSC. Many of these pathways can be halted by TH alone, whose use is linked to one of the lowest numbers-needed-to-treat (NNT) in cardiology (NNT=6). In 2003, Nolan et al. wrote the first ILCOR statement about TH after ROSC, and its indications were extended to children in 2005 and to newborns in 2010. The earlier TH is started, the better the results, while the various ways to cool the patients do not have a different impact on outcome. A simple icecold infusion can obtain patient cooling of 3.2 °C/hour, and there are data in favour of reaching a body temperature of 32°C instead of 34°C, particularly in case of ventricular fibrillation as the cause of the cardiac arrest. Rewarming is suggested at the speed of 0.2-0.3 °C/hour. Post-TH fever (> 38.5 °C), particularly if lasting more than 24 hrs, has an ominous significance. It is important to keep in mind that an early prognostication is not advisable, as in almost 10% of the patients with good prognosis, the therapy is prematurely terminated: the prognostication should not be performed before 72 hrs.

Dr. Bro-Jeppesen from Copenhagen (Denmark) addressed the issue of PCI after ROSC. It was previously demonstrated (Sunde et al.) that survival rate and good neurological outcome doubles with PCI, because around 38% of all patients with ROSC have an unstable coronary lesion at coronary angiography. On ECG recording in patients with ROSC after cardiac arrest, ST segment elevation can be demonstrated in 30-50% of the cases, according to the different series, while ST elevation was absent in 50-70% of the cases. Bro-Jeppesen et al found 93% of significant coronary lesions in patients with ST elevation on the ECG, while Dumas et al showed that successful PCI was linked to an odds ratio of 2.06 for in-hospital survival. A recent meta-analysis by Kern et al in pts with ST elevation on the ECG showed 60% overall survival, with 86% good neurological outcome. Survival is obviously better in patients with single vs multivessel disease, and is better in case of multivessel PCI than after PCI of the culprit artery only. Regarding patients without ST elevation on the ECG, the ESC guidelines on NSTE-ACS do not specifically address the issue of ROSC after cardiac arrest. Dumas et al demonstrated that patients without PCI have lower 1-year and 5-year survival and that effective PCI is linked to better survival in patients both with and without ST elevation. In conclusion, coronary angiography ± PCI can be considered in patients without ST elevation, but at high risk of coronary artery disease, with a “deferred” invasive strategy, i.e. performed within the first 24 hrs.

Finally, Prof. Deakin from Winchester (United Kingdom) addressed the issue of coronary and cerebral blood flow during cardio-pulmonary resuscitation (CPR). Two basic mechanisms should be considered, namely the cardiac pump and the thoracic pump. The heart is directly compressed between the sternum and the spine, and this can increase cardiac output and blood pressure, but only in the presence of adequate ventricular filling. On the other hand, any increase in the intra-thoracic pressure (during external chest compression, but also with cough) causes an increase in blood pressure, due to the fact that the wall of the arteries is more resistant to compression and keeps the vessel open, which is not the case of the veins. It is possible that the cardiac pump mechanism could be more important in early PCI, while the thoracic pump mechanism could be more active during prolonged CPR, cough CPR and in case of simultaneous ventilation. In animal studies, the generation of a good coronary perfusion pressure has a key role in resuscitation. As far as cerebral blood flow is concerned, it is much higher with simultaneous than non-simultaneous compression-ventilation. The use of mechanical compression devices is capable of increasing both myocardial and cerebral blood flow in animals, and the use of adrenaline further improves this favourable result.


oma

  • Senior gebruiker
  • ****
  • Berichten: 10,711


oma

  • Senior gebruiker
  • ****
  • Berichten: 10,711
Reactie #105 Gepost op: 4 september 2013, 10:23:05
Amsterdam, 4 September 2013: Close to thirty thousand delegates converged from all over the world, to the ESC Congress 2013 in Amsterdam, The Netherlands, this week. Cardiologists came to hear first-hand about the latest research.

“A record number of Hot Lines and scientific sessions with new formats allowed for more exchanges between peers presenting results of clinical trials, new Clinical Practice Guidelines and new devices and treatments,” said Professor Keith Fox, Chair of the ESC Scientific Programme Committee. We have much to learn from each other!

Some of the most important studies presented at ESC Congress 2013, according to Prof Fox were:

HOKUSAI-VTE: The oral anticoagulant edoxaban for the treatment of venous thromboembolism (VTE) resulted in equal efficacy and better safety compared to standard warfarin, when either drug was used with initial low molecular weight heparin (LMWH)

TASTE: The aspiration of the blood clot or “thrombus” that causes a heart attack before re-opening a patient’s artery with a balloon catheter does not improve survival compared to performing balloon dilation and stenting alone

REALIGN: Results reaffirm current guidelines excluding patients with a narrow QRS for CRT, and expand the body of evidence that simple electrocardiographic determination of QRS duration remains the most important predictor of the clinical benefits of CRT, rather than measures of mechanical dyssynchrony by echocardiography. Based on the results of EchoCRT, the identification of patients who will obtain the benefit of CRT can be done most easily by a 12 lead-ECG.  

DECAAF: Results showed that in patients with atrial fibrillation, delayed enhancement magnetic resonance imaging (DE-MRI) performed before ablative treatment can stage the degree of damaged heart tissue (atrial fibrosis) and help predict whether treatment will be successful or not

PRAMI: Heart attack patients with ST elevation who undergo a preventive procedure to unblock additional coronary arteries have significantly better outcomes than those whose treatment is confined to the culprit blockage only.

“These studies will influence clinical practice and will allow us to better understand how to manage these important conditions and how to devise even newer therapies,” explained Prof Fox.

“We have come a long way in cardiovascular science, but many patients in Europe still do not have access to the latest treatments. This is unacceptable.” said Professor Panos Vardas, President of the ESC.

“Just as we have tackled innovation in the past - and we still do, as the enormous amount of research presented at this Congress shows - the society is now committed to making the needs of patients known to those in charge of designing and implementing policies in European institutions and in each of our member countries. We need to fight for better healthcare and guideline implementation.” he said.

Earlier this year the ESC and its sponsors published a White Paper on the state of research and development in cardiology calling for urgent investment in CVD innovation. With a growing ageing population and considering the increase of cardio metabolic diseases, doctors are expecting the incidence of CVD to rise in the future.

“We must not forget that CVD remains the number one killer in Europe.” said Prof Vardas.

“Studies such as PURE and EUROASPIRE IV confirm these differences and also the need to strive for better and equal access of patients in all countries to better prevention programmes, to the best treatment and also rehabilitation.” Prof Vardas concluded.

“Over five hundred journalists attended ESC Congress 2013,” said Kurt Huber, Chair of the ESC Press Committee. “Once again, they helped us reach out to the public with key prevention messages. Eighty per cent of CVD could be avoided if people adopted healthier lifestyles and there is a long way to go between knowing what should be done and doing.”

Some of the most popular “stories” with the wide range of media covering the event from Amsterdam were:

The Tour de France study demonstrating that French participants in the between 1947–2012 lived longer than their same-age French counterparts

Listening to music that makes you happy and relaxed alone and in addition to regular exercise training improves endothelial function (by releasing endorphins)

Cold weather is by far the most important environmental trigger for heart attacks whereas air pollution has a lesser effect

Statins show protective effect preventing cataracts, the leading cause of visual impairment worldwide affecting more than 20 million people

Prof Fox concluded: “It was great to see hundreds of doctors cycling to the congress centre in the morning. Let’s just hope that their example will help drive home the importance of exercise to live a long and healthy life, even if we cannot emulate our Tour de France heroes!”


oma

  • Senior gebruiker
  • ****
  • Berichten: 10,711
Reactie #106 Gepost op: 4 september 2013, 17:26:08
Best of ESC Congress 2013 is a live interactive programme which reviews the latest updates in Cardiology that were presented at the congress in Amsterdam.
The event, which is hosted by a panel of international experts, evaluates how the recent development in cardiology will affect your daily practice.

http://www.escardio.org/congresses/esc-2013/Pages/bestof.aspx

Best Of ESC Congress 2013


oma

  • Senior gebruiker
  • ****
  • Berichten: 10,711
Reactie #107 Gepost op: 4 september 2013, 17:31:00
Wednesday highlights/expert analysis from ESC 2013: PURE-Sodium, TASTE (RRCT), AMADEUS.

Wednesday Highlights from ESC


oma

  • Senior gebruiker
  • ****
  • Berichten: 10,711
Reactie #108 Gepost op: 5 september 2013, 19:41:57
Oxford Journals > Medicine > European Heart Journal > EHJ at ESC, Amsterdam 201

G. Hindricks with L. Wallentin Meet the Legends September 2013

G. Hindricks with A.P. Maggioni and J. Cleland on ASTRONAUT September 2013

A. Vahanian with F. van de Werf on RE-ALIGN September 2013

U. Sechtem with N. Marrouche and G. Hindricks on DECAAF September 2013

More videos coming soon...

http://www.oxfordjournals.org/our_journals/eurheartj/esc_ams_2013.html


oma

  • Senior gebruiker
  • ****
  • Berichten: 10,711
Reactie #109 Gepost op: 5 september 2013, 20:47:47
Drs. Cannon and Bhatt discuss highlights from ESC 2013: SAVOR-TIMI 53 & EXAMINE, TASTE, PRAMI, ACCOAST, HOKUSAI VTE, RE-ALIGN, COMPARE, Colchicine in acute pericarditis.

Meeting Highlights